INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 222 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $165,000 | +81.3% | 1,333 | -3.3% | 0.00% | 0.0% |
| Q3 2019 | $91,000 | +203.3% | 1,379 | +257.3% | 0.00% | – |
| Q2 2019 | $30,000 | -65.1% | 386 | -49.1% | 0.00% | -100.0% |
| Q1 2019 | $86,000 | +16.2% | 759 | +2.7% | 0.00% | 0.0% |
| Q4 2018 | $74,000 | +29.8% | 739 | +63.5% | 0.00% | 0.0% |
| Q3 2018 | $57,000 | +46.2% | 452 | -2.8% | 0.00% | 0.0% |
| Q2 2018 | $39,000 | +62.5% | 465 | +19.2% | 0.00% | – |
| Q1 2018 | $24,000 | +200.0% | 390 | +188.9% | 0.00% | – |
| Q4 2017 | $8,000 | -33.3% | 135 | -30.4% | 0.00% | – |
| Q3 2017 | $12,000 | -72.1% | 194 | -44.4% | 0.00% | -100.0% |
| Q2 2017 | $43,000 | +437.5% | 349 | +384.7% | 0.00% | – |
| Q1 2017 | $8,000 | – | 72 | +7100.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 1 | -99.7% | 0.00% | -100.0% |
| Q3 2016 | $53,000 | +15.2% | 321 | -1.5% | 0.00% | 0.0% |
| Q2 2016 | $46,000 | – | 326 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |